Introduction
Hypersensitivity reactions, which may have various underlying mechanisms, represent a substantial medical problem during intravenous (i.v.) application of certain nanoparticlecontaining medicines. [1] [2] [3] Premedication with steroids and other anti-allergic medicines can reduce the risk and severity of such adverse reactions; however, prevention by inhibiting the triggering mechanisms, e.g. complement activation, is expected to offer more specific and effective measure against this adverse immune effect. [3] [4] [5] [6] Complement activation can underlie acute, non-IgE-mediated allergic (infusion) reactions to particulate drugs, which reactions can occasionally be severe, or even lethal. 1, 3 Thus, this phenomenon represents a major immune barrier to the therapeutic use of many state-of-the-art "nanomedicines", such as liposomal and micellar drugs and therapeutic antibodies. 3, 7 This so-called complement activation-related pseudoallergy (CARPA) is characterized by severe cardiopulmonary changes including arrhythmia, pulmonary edema, hypotension, airway occlusion, respiratory distress and cardiac arrest that in serious cases can cause anaphylactic cardiogenic shock and death. 3 Activation of the complement system leads to the formation of the anaphylatoxins C3a and C5a that can trigger mast cells and basophils to release a variety of secondary mediators with potent pathophysiological actions. 3, 8 Among these mediators, histamine, thromboxane A2 and platelet-activating factor have been shown to be causally involved in CARPA due to liposomes. 3 Complement is a main humoral defense system of innate immunity against infectious microbes. It also plays an important role in the removal of immune complexes and dying cells, and modulates the activation of cells of the innate and adaptive immune systems. 8 Complement constantly probes surfaces and can be activated via three major pathways, the classical, the lectin and the alternative pathway ( Figure 1A) . The alternative pathway (AP) is continuously activated at a low level and, independent of the initial activation route, it 4 provides strong amplification of the system, because the central C3b molecule, generated by any pathway, forms the C3bBb AP C3 convertase that cleaves additional C3 molecules into the anaphylatoxin C3a and the opsonin C3b. C3b binding to the C3 convertases shifts the ligand specificity of these enzymes that then gain the ability to cleave C5 into C5a and C5b.
C5a is a potent anaphylatoxin and inflammatory mediator. C5b initiates the terminal pathway, leading to the formation of the C5b-9 terminal complement complex, which when formed in cell membranes (then termed membrane attack complex, MAC) may cause cell lysis. Figure 1B) . Thus, FH inhibits complement activation not only in the body fluids but on host surfaces, too. 11 FH regulates complement at the AP C3 convertase level by preventing the formation of the C3bBb convertase, by facilitating its dissociation if already formed, and by assisting the protease factor I in the enzymatic inactivation of C3b. These activities render FH a potent down-regulator of complement activation ( Figure 1A) .
The antifungal drug, liposomal Amphotericin-B (AmBisome) and paclitaxel (Taxol), a widely used anticancer drug solubilized by Cremophor EL (CrEL) micelles, were shown to activate complement partly via the AP, and to induce CARPA in pigs with symptoms mimicking the human anaphylactic reaction to these drugs. 12, 13 Various therapeutic antibodies also cause hypersensitivity reactions. 3, 6 Thus, it was hypothesized that inhibition of AP complement activation might interfere with the CARPAgenic activity of these drugs.
Therefore, our aim was to assess the capacity of the natural AP regulator FH and its engineered derivative mini-FH to inhibit complement activation induced by AmBisome, CrEL and the therapeutic antibody rituximab in vitro.
Methods

Proteins, reagents and sera
Purified human FH was from Merck (Budapest, Hungary). Recombinant constructs covering were produced in insect cells as described. 14, 15 CrEL and zymosan (Zymosan-A) were from Sigma-Aldrich Ltd. 
Preparation of liposomes
The liposomes were prepared using the extrusion method. Cholesterol (Solvay Pharmaceuticals, Brussels, Belgium), hydrogenated soy phosphatidyl choline (HSPC) and 1,2-distearoy l-phosphatidyl ethanolamine-methyl-polyethyleneglycol conjugate-2000
(DSPE-mPEG2000) -all from Lipoid GmbH (Ludwigshafen, Germany) -were dissolved in 6 alcohol, mixed in molar ratios as described in Liposomes containing cholesterol-anchored PEG2000 (Chol-2P) 16 was obtained from Utrecht
Institute for Pharmaceutical Sciences (Utrecht University, The Netherlands).
Complement activation assays
CrEL was diluted to 105.4 mg/ml and zymosan to 1.5 mg/ml with phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7. 
Results
FH and mini-FH inhibit AmBisome-and CrEL-induced complement activation
To assess the efficacy of FH to inhibit liposome-induced complement activation, human serum samples were incubated with AmBisome with or without the addition of exogenous FH at the concentration of 200 µg/ml (~1.3 µM). This amount of FH approximately doubles the physiological FH concentration. SC5b-9 was detected because it is a quite stable end-product of complement activation, can be reliably measured, and is generated in parallel with C5a that is involved in the CARPAgenic effect. Serum or buffer alone resulted in baseline SC5b-9
formation, whereas AmBisome significantly increased the amounts of soluble SC5b-9.
Exogenous FH strongly and significantly reduced AmBisome-induced formation of SC5b-9
( Figure 2A ). Zymosan, a yeast cell wall extract and well-known activator of the complement 8 AP, was used as a positive control. Zymosan at 0.3 mg/ml concentration strongly activated complement and enhanced the formation of SC5b-9 in serum, which was slightly, but not significantly, inhibited by FH under the studied conditions (Figure 2A ).
To further analyze the capacity of FH to inhibit liposome-induced complement activation, liposomes of various composition were prepared, which differed in the amounts of PEG incorporated and, accordingly, caused various degrees of SC5b-9 increase when added to human serum. In all cases, addition of 1.3 µM FH reduced SC5b-9 to the background level ( Figure 2B ). This is likely due to the lower level of SC5b-9 induced compared with AmBisome ( Figure 2A ).
Previously, we described mini-FH, an artificial complement inhibitor that combines In addition, we investigated whether the FH-related CFHR1 protein, which had been described as a terminal complement pathway inhibitor, 22 influenced the formation of SC5b-9 in our assays. CFHR1 when added at 1.3 µM concentration (~50 µg/ml; estimated CFHR1 plasma concentrations are 40 µg/ml 23 and 70-100 µg/ml 22 ) did not inhibit SC5b-9 generation induced by either AmBisome (Figure 4A ) or CrEL ( Figure 4B ).
FH and mini-FH inhibit rituximab-induced complement activation in vitro
A significant proportion of patients suffer adverse reactions caused by therapeutic antibodies, even if premedication is provided. 3, 6 Rituximab, a widely used anti-CD20 mAb caused complement activation in anti-coagulated whole blood, more so when lepirudin was used as anticoagulant, compared to heparin ( Figure 5A ). FH inhibited complement activation induced by rituximab (Figure 5B ). At higher, 300 µg/ml rituximab concentration, however, 1.3 µM FH was not effective. Mini-FH strongly inhibited rituximab-induced complement activation, even at 300 µg/ml rituximab ( Figure 5B ). 
Discussion
After the discovery of the CARPA phenomenon, the application of complement inhibitors to ameliorate this adverse reaction was suggested, 24 and strategies to anchor complement inhibitor proteins or their active fragment to membranes, e.g. via a myristoyl group carrying the CCP1-3 of complement receptor type 1, were reported. 25, 26 Nanomedicines can cause complement activation via various pathways, and theoretically each of these activation pathways could specifically be inhibited by a suitable inhibitor, e.g. C1 inhibitor for the classical/lectin pathways. We aimed to investigate an inhibitor that could likely be more broadly used. Because FH is a major inhibitor at the level of the central C3 complement component and that of the AP amplification loop (Figure 1A) , it is an ideal regulator to reduce or even prevent generation of the C3a and C5a anaphylatoxins, and also that of C5b-9, particularly, because complement activation by any pathway would be amplified through this loop. [8] [9] [10] [11] 27 In addition, it was reported that FH could inhibit the classical pathway on ligands where FH can compete for binding with C1q, 28 which may also play a role in the case of certain nanomedicines. FH, and showed its efficacy in reducing C3 turnover also in vivo. 31 The enhanced activity of mini-FH is likely due to the increased availability of the C-terminal glycosaminoglycan/C3d binding sites in the shorter molecules, which are probably partly hidden in the full-length FH.
In agreement with these previous results using different types of complement activation assays, on a molar basis mini-FH was more active than FH in preventing liposome-and rituximab-induced complement activation (Figures 3 and 5) . Thus, engineered FHderivatives may prove useful to effectively down-regulate such adverse complement reactions. While mini-FH in its current form, owing to its small size, is rapidly cleared from the circulation, it still could be useful especially to inhibit CARPA, which is a relatively quickly arising adverse reaction and thus the short-term inhibitory effect of mini-FH, when co-administered with or even coupled to the potentially CARPA-genic drug, could be satisfactory to prevent or reduce CARPA.
The background mechanism and the extent of complement activation differ due to the various composition, surface charge, size and physical properties etc. of the liposomes, micelles and other nanocarriers. 3 The amount and nature of deposited C3 fragments, as well as the physico-chemical properties of the surfaces, also influence the potential interaction of FH with these surfaces. These at least in part explain why the same amount of tested FH resulted in different degree of inhibition; for example, the stronger complement activation and thus higher SC5b-9 levels induced by AmBisome could only partially be inhibited by FH and completely by mini-FH, whereas in the case of CrEL, the less amount of SC5b-9 was fully inhibited by both FH and mini-FH, both applied in 1.3 µM in the assays (Figure 3 ).
Altogether these results suggest that an engineered mini-FH-like derivative of FH could be more useful for inhibitory purposes than the native molecule, because it is a more potent complement inhibitor and can also be produced in a more controlled way.
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The FH-related CFHR1 protein was previously described as a novel complement inhibitor that binds to C5 and down-regulates the terminal pathway, 22 which effect could not be confirmed by other investigators. [32] [33] [34] [35] We tested recombinant CFHR1 for its capacity to influence SC5b-9 formation in the liposome-and CrEL-induced complement activation assays in vitro and found no inhibitory effect of this FH-related protein (Figure 4) . While this 13 does not exclude a potential of CFHR1 to regulate cell membrane integrated C5b-9, these results question a general terminal pathway inhibiting function of the protein.
Hypersensitivity or infusion reactions, mediated in part by complement activation, can be observed in a substantial number of patients when administering therapeutic mAbs. 6 Although such reactions do not affect every patient, reactions to various extent were reported in the case of the different mAbs (from <1% to over 50%), and even fatal reactions occur. 36 For rituximab, adverse reactions were reported in up to 85% of patients, with 2-10% being severe reactions and 0.04-0.07% being fatal. 37 In our assays, FH and mini-FH were able to reduce or inhibit rituximab-induced complement activation in serum in vitro ( Figure 5 ). This is most likely due to fluid-phase inhibition of complement activation by FH and mini-FH.
The mechanism of action of rituximab on the target B cells involves complementdependent lysis, antibody-mediated cellular cytotoxicity and induction of apoptosis; however, it is still unknown which of these is the most important mechanism. 38 FH when bound from serum to the cells can reduce the efficacy of complement-mediated B cell killing due to its inhibitory nature. 39 We found, however, that FH1-4, which can be used to inhibit complement activation in serum (Figure 4 ) but cannot bind to the cell surface, does not substantially decrease the efficiency of surface-bound rituximab to induce complement-mediated killing of B cells (Figure 6 ).
There are differences among individuals in the rate of complement activation, which is influenced by serum levels and functional variants of complement proteins and regulatory molecules, such as those of FH. For example, the FH level varies substantially among individuals (124.4-402 µg/ml). 40 The specific set of complement gene variants, termed complotype, determines how quickly and to what extent complement activation occurs under given circumstances in serum of a person, and influences the risk to inflammatory and infectious diseases. 41 This likely explains the observed differences in AmBisome-and CrEL-14 induced SC5b-9 production in the sera of the various donors (Figures 3 and 4) . While genetic analysis to determine the complotype and measurement of protein levels are time-consuming and costly, the capacity of given nanomedicines to induce complement activation in serum or blood of a patient can be tested relatively easily in a functional assay, as also shown here. 42, 43 In summary, our data suggest that FH or its derivatives like mini-FH could be a potentially useful approach to prevent complement activation and thus CARPA caused by a variety of nanomedicines, monoclonal antibodies and other agents. When the mechanism of action of a therapeutic antibody involves complement-dependent cytotoxicity, such as in the case of rituximab, a FH construct that does not bind to cells, e.g. FH1-4, may be considered.
Importantly, with a relatively simple test patients can be pre-screened for proneness for CARPA and thus a complement inhibitor may be applied when indeed necessary.
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Figure legends (B) Liposomes of various compositions were prepared as described in Methods and Table 1 , and caused various degrees of complement activation when added to normal human sera as in (A). FH was added at 1.3 µM concentration. Chol-2P: liposomes containing cholesterolanchored PEG2000. 16 Data are mean + SEM of at least three measurements. *, p < 0.05, **, p < 0.01 and ***, p < 0.001, Student's t-test. ns, not significant. 
